Moderna and Medison Pharma partner to commercialize Moderna’s COVID-19 vaccine across Central Eastern Europe and Israel

CAMBRIDGE, Mass. and ZUG, SwitzerlandJune 7, 2021 /PRNewswire/ -- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines and Medison Pharma, a leading commercial partner for highly innovative therapies in international markets, today announced a new agreement to commercialize the Moderna COVID-19 Vaccine across Central Eastern Europe and Israel.

The agreement covers the following countries: PolandCzech Republic, Romania, Hungary, BulgariaSloveniaSlovakiaCroatiaEstoniaLatviaLithuania, Serbia, Ukraine, MoldovaAlbaniaBosnia and HerzegovinaKosovoNorth MacedoniaMontenegro, and Israel.

"We are excited to partner with Moderna in 20 markets, covering over 175 million lives across the entire Central Eastern Europe region and in Israel," said Meir Jakobsohn, Founder and CEO of Medison Pharma. "Moderna's breakthrough mRNA vaccine and Medison's international commercialization platform for highly innovative treatments, makes our partnership a natural fit."

"We appreciate this new partnership with Medison Pharma to ensure successful delivery of our mRNA COVID-19 vaccine to market," said Corinne Le Goff, Pharm.D., M.B.A., Chief Commercial Officer of Moderna. "Working together with our partners, we remain steadfast in our commitment to fighting the pandemic by delivering our vaccine to populations globally."

For the complete Press Release: